Expression Pathology Signs Biomarker Discovery Deal with Digene

Expression Pathology Inc. has announced that it has entered into research collaboration with Digene Corporation to identify cancer protein biomarkers in archived tissue using Expression Pathology’s proprietary Microproteomics Biomarker Discovery platform.

Under the terms of the agreement, Expression Pathology will employ its Liquid Tissue™ MS Protein Prep reagents with LC MS/MS mass spectrometry to identify proteins in microdissected formalin-fixed tissue of known pathology and clinical history.